Heart Disease

Clinical trials to determine optimal Aggrastat therapy for PCI patients

Published in Drug Week, September 10th, 2004

Guilford Pharmaceuticals Inc. (GLFD) announced plans to launch two major trials for Aggrastat Injection (tirofiban hydrochloride) that are designed to determine the optimal therapeutic regimen for patients at the time of percutaneous coronary intervention (PCI).

Guilford plans to conduct the first trial outside the United States as a multi-center, double-blind, placebo-controlled trial evaluating the 30-day efficacy of the single high-dose bolus regimen of Aggrastat compared to placebo in high-risk patients undergoing PCI with coronary stent placement.

The trial is expected to enroll approximately 2000 patients in 100 centers. According to present...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-09-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry